Maxis Gbn Recognized For Excellence In Captive Insurance—wins Captive Healthcare Specialist Of The Year Award

Organized by Captive Review, the UK Captive Services Awards, recognize excellence in the delivery and management of captive insurance. Being named the Captive Healthcare Specialist of the Year is an honor, and reflects MAXIS GBNs commitment to providing tailored solutions and world-class services that meet the business needs of our multinational customers, said Jim Peiffer, managing director, MAXIS GBN, and senior vice president, MetLife. By understanding and aligning our customers global and local priorities, we are able to help our customers manage their worldwide employee benefits programs through flexible and innovative solutions, including our industry-leading health and wellness programs. The UK Captive Services Awards recognize companies that have outperformed their peer group over the course of the past year. The awards are judged on the criteria of 1) company growth: client numbers, premium/assets under management, internal hires, geographic expansion; 2) client satisfaction; 3) genuine product innovation; and 4) adaptability: in the face of client demands and new regulation, etc. The judging panel consists of representatives from Captive Review, industry experts and corporate risk managers. “The Captive Healthcare Specialist Award is a prestigious one, as medical captives represent a thriving, fast growing sector of the captive industry. MAXIS GBN is not only a leader in the medical captive space, but goes the extra mile when it comes to data analysis and implementation of risk management initiatives that ultimately benefit the health of the insureds,” said Antony Ireland, acting editor, Captive Review. The award recognized MAXIS GBN for its leading healthcare management and wellness solutions. MAXIS GBN offers through its members, medical insurance and health and wellness capabilities in 85 markets with over four million insureds. With its customer-centric focus, MAXIS GBN delivers customer-specific analysis of medical claims, research insights on wellness, client discussion forums, and perspectives on local health and wellness solutions. About MAXIS GBN MAXIS GBN was founded in 1998 by AXA and MetLife, two leading global insurers. MAXIS GBN includes locally licensed member insurance companies in over 110 countries, is trusted by over 750 multinational employers and covers 1.5 million employees worldwide. For more information, please visit http://www.maxis-gbn.com .
http://www.businesswire.com/news/home/20140306005932/en/MAXIS-GBN-Recognized-Excellence-Captive-Insurance—Wins-Captive

Palliative specialists support UK care pathway

A similarly high number of doctors indicated that they would want the pathway themselves if they were terminally ill, show the results. “The Liverpool care pathway is the most widely used integrated care pathway for end of life care, but it has recently been criticised after accounts in the media of patients having food and fluids withdrawn and hospitals being offered financial incentives for using the pathway,” writes Krishna Chinthapalli (British Medical Journal [BMJ], London, UK) in the BMJ. The journal emailed 3021 hospital doctors to gauge their views of the care pathway, which engages a multidisciplinary team to assess whether a patient is indeed dying, and to consider and agree on palliative care options, including whether nonessential treatments and medications should be discontinued. Of the 647 respondents, 185 were palliative medicine consultants, 168 were doctors in training or career grade posts in palliative medicine, and 210 were doctors of other specialties. A total of 87% reported having used the LCP in clinical practice. However, 57% of respondents felt that recent negative press in the UK media has led to the care pathway being used less. Almost three-quarters (74%) of palliative medicine specialists felt this way. Indeed, 60% of doctors who believed there was less use of the pathway as a result of a negative perception in the UK media said that relatives of dying patients had asked them not to use it, and that 80% of staff were apprehensive about it. One palliative medicine specialist said: “Negative press regarding the LCP has caused additional distress for relatives at an already distressing time when their loved one is dying. This has caused a dilemma in judging if discussing the LCP will cause more distress than the benefit of being on the LCP.” Notably, 90% of doctors said that they would want the pathway themselves during a terminal illness, although the questionnaire did not make it clear whether that meant dying from a terminal illness.
http://www.news-medical.net/news/20130306/Palliative-specialists-support-UK-care-pathway.aspx

Advertisements

Celiac Disease: Getting To Know The Gastroenterologist

The GI will take a medical history and do a complete physical exam, and possibly a rectal exam if youre experiencing bloody stools. If celiac disease is suspected, the gastroenterologist will order blood tests (known as a celiac panel) to help diagnose celiac disease. It can take between three days and two weeks to receive the results, Verma says. Then the next step is to schedule an endoscopy. An endoscopy involves passing a small tube with a camera on the end of it into the mouth, through the stomach, and into the small intestine. Biopsies (tissue samples) can be taken of the small intestine to confirm the diagnosis of celiac disease. Your First Gastroenterologist Visit: How to Prepare To prepare for your first visit to the gastroenterologist: Dont change your diet. The most important thing, if you think you might have celiac disease, is to not modify your diet. If you start a gluten-free diet beforehand, celiac testing wont be accurate, Verma says. Bring copies of relevant test results. If any blood work has been done previously, make sure to bring that along. Verma suggests. Even if the doctors office says they will send it, sometimes things get lost. Its a good idea to bring that paper with you. Know and share your family medical history. Knowing whether celiac disease runs in your family can help your doctor make the right diagnosis . If theres a family history of celiac disease, testing will get done faster, Verma says. Be prepared to describe your symptoms in detail.

hop over to this web-site http://www.everydayhealth.com/celiac-disease/celiac-disease-guide-to-gastroenterologist.aspx

Gastroenterologist Peyton P. Berookim Rated Best GI in Los Angeles

However, there are some tips that can make finding a qualified and caring gastroenterologist easier. Recommendations from family, friends, and co-workers can help. So too, can looking at certifications, awards, and where the physician has admitting privileges, and even Yelp reviews can be very helpful. A look through all of these qualifications might lead one to Dr. Berookim , MD, FACG, a double-board certified and award-winning gastroenterologist based in Beverly Hills, who has gotten high ratings from patients. A highly qualified Beverly Hills GI doctor, Dr. Berookim has received numerous awards. Among the honor hes received include: Americas Top Gastroenterologist, Americas Top Physicians, UCLA Chancellors Humanitarian Award, Patients’ Choice Award, and a Best of Beverly Hills Award. Whats more, Dr. Berookim has admitted privileges at Cedars-Sinai Medical Center, one of the top hospitals in the U.S. (ranked #13 in the 2013 U.S. News & World Report). He has also received high ratings on Yelp, with patients rating him an overall average of 4.5 stars out of 5.

check this http://www.sbwire.com/press-releases/best-gastroenterologist-in-beverly-hills-meet-dr-berookim-408226.htm

Best Gastroenterologist in Beverly Hills, Meet Dr. Berookim

Berookim is a double-board certified gastroenterologist practicing in Beverly Hills who treats patients with GI issues and problems in the Los Angeles area. Call 310-271-1222 to learn more about the services Dr. Berookim provides, or to schedule an appointment with him. Looking for a qualified and caring gastroenterologist who treats patients with a variety of GI issues in the Los Angeles area? Then look no further than Dr. Peyton P. Berookim, MD, FACG , a double-board certified gastroenterologist with a record of providing top-quality and compassionate care to his patients. Based in Beverly Hills at the Gastroenterology Institute of Southern California , Dr. Berookimspecializes in the prevention and treatment of a number of digestive track disorders and conditions. He also performs important medical screening exams, including colonoscopies and endoscopies. Dr.

company website http://www.sbwire.com/press-releases/gastroenterologist-peyton-p-berookim-rated-best-gi-in-los-angeles-413419.htm

Uk Has Fewer Doctors Per Person Than Bulgaria And Estonia

Egypt doctor faces trial over fatal female genital mutilation

The UK ranked 24th out of the 27 European nations, only beating Slovenia, Romania and Poland according to the data, published by the EU Commission as part of its Eurostat regional yearbook 2013. By comparison there were more than six doctors per 1,000 people in Greece, which tops the list, nearly five in Austria and just under four in Italy. The figures, showing the number of physicians practising in all EU countries during 2010, come after a string of events which critics say show the NHS faces a staffing crisis. Related Articles English education system among most class-ridden in developed world 29 Jan 2014 Last summer MPs on the Health Select Committee warned that only one in five casualty wards in England had enough consultants on duty, leading it to conclude that A&E departments are in crisis. Rehana Azam, GMB National Officer for the NHS said: “Enough is enough, there can be no more cuts to budget or staffing. “There is so much pressure on NHS staff because of the shortage and the huge number of patients they treat. It’s extremely worrying, particularly as we are facing the toughest winter in years. Dr Paul Flynn, Chair of the British Medical Association Consultants Committee, said: Policy makers need to get a grip on NHS workforce planning. Projected imbalances between different specialties will have serious implications for patient care and we are already seeing the effect of staff shortages in key areas such as emergency care. In addition, despite the pledge to protect front-line services, many employers in the NHS are freezing recruitment in response to financial pressures. Dr Flynn said that staffing levels must be aligned to meet the changing demands of patients and address issues such as workload pressures and work-life balance that might be deterring medical graduates. Doctors in the NHS face increasingly challenging, high pressured and stressful work environments, often with limited resources and gruelling workloads. Only by making working practices and environments safe and sustainable will the NHS be able attract and retain the required number and mix of doctors, he said. According to OECD data, the number of doctors per head of population in the UK has been increasing from just 1.9 per 1,000 in 2000, when European average stood at 2.9. The UK has seen more rapid growth than others, narrowing the gap against the European average, which had grown to 3.4 per 1,000 in 2010. The OECD says the number of doctors in the UK increased again in 2011, to 2.8 per 1,000. Analysis by Plaid Cymru last year showed Wales had the fewest doctors per 1,000 at 2.5, while England and Northern Ireland had 2.7 per 1,000. Scotland by contrast dragged up the average, with 3.1 per 1,000.

more information http://www.telegraph.co.uk/health/10550335/UK-has-fewer-doctors-per-person-than-Bulgaria-and-Estonia.html

Some senior NHS doctors are claiming more than £150,000 in overtime to care for patients out of hours, it has been disclosed.

The 14-year-old girl’s father who took her to the doctor for the procedure will also face trial, the official said. Although banned in 2008, female genital mutilation is still rampant in Egypt, especially in rural areas where many believe it is part of their faith. The doctor in the Nile Delta city of Mansoura performed the dangerous procedure at a private clinic. The operation involves the removal of the clitoris and sometimes even more extreme mutilation, which proponents argue ‘purifies’ women from sexual temptation. The practice has been common among both Muslims and minority Christians, said Nehad Abolkomsan, who heads the Egyptian Centre for Women’s Rights. A survey in 2000 said the procedure had been carried out on 97 percent of the country’s married women. The fight against the practice was dealt a setback by Islamists after president Hosni Mubarak’s overthrow in 2011, who argued women’s rights laws were vestiges of the dictator’s regime, Abolkomsan said. She said efforts to reach out to rural areas to end the practice had been partially successful, but more government supervision was needed. “This will continue to need a lot of work and effort by the state to apply the law,” she said. “Most cases don’t get to the attention of the prosecutor, unless the girl suffers health consequences.” The practice is also common in other African and Middle Eastern states. The World Health Organisation estimates that between 100 million and 140 million women have been victims of genital mutilation worldwide.

look at here now http://uk.news.yahoo.com/egypt-doctor-faces-trial-over-fatal-female-genital-145304693.html

Doctors less likely to adjust depressed patients’ blood pressure drugs

For their study, Moise and her colleagues examined the medical records of 158 people with uncontrolled high blood pressure seen at one of two inner-city primary care clinics in New York City. Most patients were women, Hispanic and in their 60s or older. About 45 percent had been diagnosed with depression. The researchers defined clinical inertia as a lack of changes in medication, referral to a hypertension specialist or intensive evaluation despite high blood pressure that wasn’t kept in check by a patient’s current drugs. They reported in JAMA Internal Medicine that people with depression had a 49 percent higher risk of clinical inertia than those who weren’t depressed. Moise said doctors could be assuming that depressed people aren’t as good about taking their medication, but that wasn’t the case among patients in her study. It’s also possible that depressed patients have a lot of other medical conditions that need to be addressed during any given visit. “I think awareness is very important and I also think that because depression is associated with worse outcomes and other chronic illnesses such as diabetes, for instance, it would really be interesting to see whether or not we would be able to replicate these findings (among people with other chronic diseases),” Moise said. “I think that the fact that research like this is being done is very important because it focuses on making sure we can optimize healthcare delivery to people, particularly those at greatest risk for heart disease,” Dr. Nieca Goldberg told Reuters Health. Goldberg is medical director of the Women’s Heart Program at NYU Langone Medical Center in New York City. She was not involved in the new study.

at yahoo http://uk.reuters.com/article/2014/03/10/us-doctors-less-likely-idUKBREA291JV20140310?feedType=RSS&feedName=healthNews

Maxis Gbn Recognized For Excellence In Captive Insurance—wins Captive Healthcare Specialist Of The Year Award

GE Healthcare completes acquisition of Finnamore to form leading UK specialist health and social care consultancy

MAXIS Global Benefits Network (GBN) was named the Captive Healthcare Specialist of the Year at the second UK Captive Service Awards. Organized by Captive Review, the UK Captive Services Awards, recognize excellence in the delivery and management of captive insurance. Being named the Captive Healthcare Specialist of the Year is an honor, and reflects MAXIS GBNs commitment to providing tailored solutions and world-class services that meet the business needs of our multinational customers, said Jim Peiffer, managing director, MAXIS GBN, and senior vice president, MetLife. By understanding and aligning our customers global and local priorities, we are able to help our customers manage their worldwide employee benefits programs through flexible and innovative solutions, including our industry-leading health and wellness programs. The UK Captive Services Awards recognize companies that have outperformed their peer group over the course of the past year. The awards are judged on the criteria of 1) company growth: client numbers, premium/assets under management, internal hires, geographic expansion; 2) client satisfaction; 3) genuine product innovation; and 4) adaptability: in the face of client demands and new regulation, etc. The judging panel consists of representatives from Captive Review, industry experts and corporate risk managers. “The Captive Healthcare Specialist Award is a prestigious one, as medical captives represent a thriving, fast growing sector of the captive industry. MAXIS GBN is not only a leader in the medical captive space, but goes the extra mile when it comes to data analysis and implementation of risk management initiatives that ultimately benefit the health of the insureds,” said Antony Ireland, acting editor, Captive Review. The award recognized MAXIS GBN for its leading healthcare management and wellness solutions. MAXIS GBN offers through its members, medical insurance and health and wellness capabilities in 85 markets with over four million insureds. With its customer-centric focus, MAXIS GBN delivers customer-specific analysis of medical claims, research insights on wellness, client discussion forums, and perspectives on local health and wellness solutions. Stock quotes in this article: MET

original site http://www.thestreet.com/story/12520308/1/maxis-gbn-recognized-for-excellence-in-captive-insurance–wins-captive-healthcare-specialist-of-the-year-award.html

The acquisition will see GE Healthcare’s UK consultancy arm, formerly Performance Solutions UK, become GE Healthcare Finnamore, expanding its employee base to 70, many of whom are former clinicians, engineers and management consultants. The new firm will be led by John Deverill, formerly Managing Director of Finnamore. GE Healthcare Finnamore will be focused on partnering with NHS and other UK health and social care providers to help them improve operational efficiency, clinical outcomes and patient experience. The company will offer strategic consulting capabilities across integrated care, performance transformation, organizational development, finance and change management. Top Company Interviews Finnamore brings award winning expertise and relationships built over 20 years of operating in the UK market, to complement GE Healthcare’s existing consultancy expertise and UK client base. John Deverill, Managing Principal, GE Healthcare Finnamore said: “This brings Finnamore together with one of the world’s leading healthcare companies, both with a shared vision to improve health and well-being and to support the development of patient-focused, integrated care. We are creating an organization that can grow and broaden its capabilities to help the NHS and other health and social care providers to improve their financial, operational and clinical performance on a sustainable basis using consultancy, technology, data analytics, and capital.” The acquisition is part of GE Healthcare’s strategy to help healthcare providers navigate some of their most complex challenges in a climate of increased budgetary pressures as chronic disease incidence increases amongst an ageing population. Karl Blight, GE Healthcare’s General Manager in UK, said: “GE Healthcare is investing in advisory capabilities as part of the company’s objective to become a true strategic partner to our customers. GE Healthcare Finnamore’s consultants bring a real depth of expertise to help our UK customers address many of the efficiency challenges they face day to day.” Andy Ward, former head of Performance Solutions UK, who will now lead GE Healthcare’s consultancy work across Northern Europe while continuing to advise the UK team during the integration period, explained: “NHS England recently cited a potential 30 billion funding gap by 2020-21 if services continue to be delivered in the same way. We are well positioned to help combat that, drawing from GE’s heritage of performance improvement and operational management, and Finnamore’s experience of quality delivery in the UK. This acquisition increases our scale and expertise to help our customers optimize capacity and ensure that patients are cared for and treated as efficiently and effectively as possible.” GE Healthcare Finnamore will be based in London, close to GE Healthcare’s global HQ in Amersham.

check this site out http://www.twst.com/update/34239-ge-general-electric-company-ge-healthcare-completes-acquisition-of-finnamore-to-form-leading-uk-specialist-health-and-social-care-consultancy

An Australian Audit Of Vaccination Status In Children And Adolescents With Inflammatory Bowel Disease

Optiscan Imaging’s endomicroscope being used in clinical gastroenterology study

Optiscan is focused on microscopic imaging technologies for medical markets.

Despite small numbers of patients, it highlights the need to discuss the risk versus benefits of live attenuated vaccines on a case-by-case basis. Another approach is to review the immunization status at diagnosis and give all recommended vaccines (e.g. varicella, hepatitis B) before commencing immunosuppressive therapy. This, however, is becoming a smaller window of opportunity with the earlier use of immunomodulatory therapy in IBD. A limitation of the study is the retrospective nature of the review in a state based IBD population. It was a representative sample of the database, but some IBD patients may have been excluded if seeing a private and/or adult gastroenterologist and not placed on the register. One major difficulty in conducting the study was uptake of ‘opt in’ consent, reflected by only 53% of adolescent and young adult patients being contactable. These are common issues in retrospective health related research and a number of surveys have explored the importance of exploring meaningful non-consent and considering ‘opt out’ consent [ 43 , 44 ]. The study was powered for 100 audit participants, but the results were affected by the low recruitment for the telephone immunization status review. The reported proportions of participants receiving the additional pneumococcal and influenza vaccines may not reflect the actual immunization status due to this incomplete record obtainment. The study was also underpowered to detect differences in the characteristics of those who received influenza vaccine. Another limitation is that the ACIR only routinely captures and maintains immunization records in children < 7 years of age, so added little information in this predominantly adolescent population. Whilst ACIR can include additional vaccines (e.g. influenza and pneumococcal), this information is not always captured. Suboptimal compliance with annual influenza vaccination and other additional vaccines recommended could be due to lack of awareness or acceptance of immunization guidelines for IBD patients.

source news http://www.biomedcentral.com/1471-230X/11/87

Optiscan Imaging (ASX: OIL) has noted commencement of a clinical study that is introducing Optiscan’s second generation endomicroscopy platform into the field of gastroenterology. The study is being undertaken by gastroenterologists and scientists from the Garvan Institute of Medical research and St Vincent’s Hospital in Sydney, in affiliation with the University of New South Wales. The gastroenterology market is now well established as a result of extensive use of Optiscan’s previous generation platform via a product marketed by Pentax Medical Corporation. The study has enabled the incorporation of the latest advances in Optiscan’s technology into a high definition Olympus endoscope. The resultant system combines advanced features of the Olympus endoscope with Optiscan’s latest developments in microscopic imaging during endoscopy. The result is an endoscope with a level of performance never before trialled in humans, incorporating desirable features discovered using the first generation product during thousands of endoscopy procedures, and other advances in endoscopic imaging. This study will apply these novel features in dynamic events relating to the permeability, or “leakiness” of the gut lining and how it is altered by inflammatory diseases. For Optiscan, the commencement of patient recruitment in this study is a key milestone in its strategy to advance the second generation platform into commercially viable markets. The same platform is currently the subject of product development for neurosurgery under a commercial partnership with Carl Zeiss of Germany, as well as a supply agreement recently secured with UK based MR Solutions for global supply into the pre-clinical imaging market. Optiscan is capitalised at around $10 million. Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX Small and Mid-cap stocks with distribution in Australia, UK, North America and Hong Kong / China.

this review http://www.proactiveinvestors.com.au/companies/news/53333/optiscan-imagings-endomicroscope-being-used-in-clinical-gastroenterology-study-53333.html

Woman Drives Into Doctor’s Office, Pinning 3 Inside: Police

Woman Drives Into Doctor’s Office, Pinning… Link Close Embed this video More videos (3 of 9) More Photos and Videos A 75-year-old woman drove her car into a doctor’s office on Long Island Tuesday, hurting three people inside, authorities say. The car pinned three people inside the waiting room on Middle Country Road in Smithtown just before 4:30 p.m. Tuesday, authorities say. A doctor, a 9-year-old patient and his mother were taken to Stony Brook Hospital with minor injuries. The driver, who was also taken to the hospital, was OK, but “very shook up,” according to Smithtown Assistant Fire Chief Kevin Fitzpatrick. Dr. Richard Ancona was tending to a patient at Branch Pediatrics when he heard the impact echo throughout the building. “It just lasted 20 to 30 seconds, it wasn’t a quick 1-2-3,”said Ancona. “I ran around to the other side and I couldn’t believe when I ran down the hall, I see the front of the car sticking out of the room.” Authorities are investigating how the woman’s car left the driveway to veer right and end up in the side of the building. No charges have been filed. Contractors were expected to clean up the site overnight so that the doctor’s office could reopen Wednesday.

in the know http://www.nbcnewyork.com/news/local/Elderly-Woman-Drives-Into-Building-Doctors-Office-Long-Island-248441231.html

Man Pleads Guilty to Stealing SC Doctor’s Identity

Attorney DeWayne Pearson said the men planned to open a medical clinic in the United States. Kennedy gave Addo documentation of his own medical training but remained in Ghana to teach. Using Kennedy’s information, prosecutors said Addo obtained a South Carolina driver’s license and created an online profile with a physician employment agency, which placed him for a short time at a job in Greenwood. Addo also later worked for a facility operated by the South Carolina Department of Mental Health before being matched with Agape Senior Primary Care. Addo attended medical school in Belize, but Pearson said that authorities could not independently confirm he had passed medical board examinations there. For about six months, Addo saw patients at several Agape facilities in the Columbia area, performing the sort of exams someone might get during a visit to a family doctor. Authorities have also said he wrote some prescriptions, including some for himself. Addo faces no charges of physically harming any patients. Pearson said authorities were notified in 2012 after Kennedy’s wife received a statement for a credit card that had been opened in her husband’s name. She confronted Addo, who admitted he had stolen the doctor’s identity. Part of the fraud allegations relate to Medicaid and Medicare billings that Agape submitted for patients treated by Addo, Pearson said. In all, the agencies paid out $400,000 in those cases, he said. When Addo was arrested, Sheriff James Metts said his crimes appeared to be motivated by greed.

see this website http://abcnews.go.com/US/wireStory/man-pleads-guilty-stealing-sc-doctors-identity-22770019

Canadian Independent Medical Study Shows Bio-k+cl1285(r) Can Prevent Antibiotic-associated Diarrhea

Bio-K+CL1285(R) is currently used in 36 Canadian hospitals and health centres, and is sold in the health specialized sections of grocery stores, pharmacies and health stores across Canada and US. About Bio-K+ International Inc. Founded in 1994, Bio-K+ International Inc. is a family-owned Canadian biotech company with its head offices located in Laval’s scientific and high-tech park. With more than 65 employees, Bio-K+ International Inc. is dedicated to the manufacture, distribution and sale of Bio-K+CL1285(R) products. For more information, please visit the web site http://www.biokplus.com . Canadian Journal of Gastroenterology: http://www.pulsus.com/journals/toc.jsp?sCurrPg=journal&jnlKy =2&fold=Current%20Issue—————————— (1) Effect of fermented milk combining Lactobacillus acidophilus CL1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: A randomized, double-blind, placebo-controlled trial, CANJ Gastroenterology, Vol 21, No 11, November 2007, 732:736. (2) Product and placebo were provided by Bio-K+ International Inc, which also provided a research grant to cover the pharmacy administration fees. (3) Canadian Bacterial Surveillance Network, February 2006, and CMA Foundation, 2006. (4) McFarland LV.

top article http://www.newswire.ca/en/story/48629/canadian-independent-medical-study-shows-bio-k-cl1285-r-can-prevent-antibiotic-associated-diarrhea

REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients

The REACT (Randomized Evaluation of an Algorithm for Crohn’s Treatment) study, led by Robarts Clinical Trials at Western University (London, Canada) provides valuable new insights for community gastroenterologists which should benefit patients. The results of the study will be presented at the European Crohn’s and Colitis Organisation (ECCO) annual congress taking place in Copenhagen, Denmark on February 20-22, 2014. Crohn’s disease is a chronic, potentially debilitating, condition of the gastrointestinal tract which can cause abdominal pain, diarrhea, vomiting, and weight loss among other symptoms. Well over five million people globally are affected by Crohn’s disease and ulcerative colitis. Dr. Brian Feagan, CEO and Senior Scientific Director of Robarts Clinical Trials and a professor in the Division of Gastroenterology at Western’s Schulich School of Medicine & Dentistry, says the medical management of Crohn’s disease has undergone important changes over the past two decades with the introduction of TNF antagonists such as adalimumab and infliximab. The current treatment approach features sequential and incremental treatment intensification based on symptoms. In contrast, an accelerated step-care approach involves the early introduction of combined immunosuppression in high risk patients, which has been shown to induce and maintain remission, reduce the use of corticosteroids, and heal intestinal ulceration in those who fail conventional treatment. Subsequent research, performed in both Crohn’s disease and rheumatoid arthritis, indicated that TNF antagonists work best when: 1) used in combination with antimetabolites (e.g., azathioprine, methotrexate) and 2) introduced early in the course of the disease. Controlled studies such as CHARM (Crohn’s Trial of the Fully Human Antibody Adalimumab for Remission Maintenance) have also demonstrated that TNF antagonist-based regimens can reduce the rate of surgery and hospitalization in comparison to conventional therapy. “However, adoption of these key concepts by community gastroenterologists has been relatively slow,” says Dr. Feagan. “This is primarily because many believe that the safety and efficacy of these agents may not be generalizable to their individual practice, since they were tested in academic centers. The REACT study was designed to address these concerns.” In this cluster-randomized trial, 39 community gastroenterology practices in Canada or Belgium were randomly assigned to a conventional management approach or to an accelerated step-care algorithm that featured early use of combined adalimumab/antimetabolite therapy. Within practices, up to 60 consecutive patients were entered and evaluated for 24 months to determine whether the implementation of an accelerated step-care approach would improve the management of Crohn’s disease in comparison to conventional management methods. Final results from the REACT clinical trial showed the proportion of patients in remission at 12 months was marginally greater in the group assigned to accelerated step-care.

explanation http://www.news-medical.net/news/20140224/REACT-clinical-trial-provides-valuable-new-insights-for-community-gastroenterologists-that-benefit-patients.aspx

Atlanta-Based EndoChoice Approved To Market Full-Spectrum Endoscopy System In Canada

The Fuse endoscopy system is comprised of colonoscopes and gastroscopes with multiple imagers enabling doctors to see more of the GI tract for diagnosis and treatment. Standard, forward-viewing endoscopy systems have a single imager so clinicians are switching to the Fuse system in an effort to improve the quality of their procedures. The Health Canada license means its Fuse system will be the first endoscopy equipment available with expanded viewing capabilities to reach Canadian patients, the company said. Endoscopes are thin flexible tubes with imaging capabilities that doctors use to view the upper and lower GI tracts of their patients. The news from Health Canada enables EndoChoice to begin delivering Fuse endoscopy systems to their gastroenterology specialist customers throughout Canada . “We intend to gain market clearance in several more countries in the near future,” said Mark Gilreath, Founder and CEO at EndoChoice. “While 2013 has been an exciting year for our company, the introduction of Fuse into Canada and other markets will enable us to make 2014 even more dynamic as we bring this game-changing technology to more clinicians.” EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal diseases. EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide. The Company was founded in 2008 and has rapidly developed a proprietary product portfolio.

the advantage http://www.areadevelopment.com/newsItems/1-20-2014/endochoice-license-approval-canada912390.shtml